NASH - Nonalcoholic Steatohepatitis Clinical Trial
Official title:
Effectiveness and Safety of Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis
Verified date | June 2024 |
Source | Al-Azhar University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the present study is to evaluate the efficacy and safety of pentoxifylline in the treatment of non-alcoholic steatohepatitis patients.
Status | Completed |
Enrollment | 50 |
Est. completion date | October 1, 2022 |
Est. primary completion date | September 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Aged between 18- 60 years old. 2. Both sexes 3. Patients who have nonalcoholic steatohepatitis (NASH) will be diagnosed by 1. clinical examination (obese, high body mass index). 2. radiological criteria of fatty liver (abdominal ultrasonography). 3. laboratory investigation (elevated liver enzymes aspartate transaminase (AST), alanine transaminase (ALT). 4. The ability to give informed consent 5. Appropriate exclusion of other liver diseases Exclusion Criteria: 1- Patients with other diagnosed chronic liver diseases as viral hepatitis, metabolic and genetic disorders as Hemochromatosis, Wilson disease, autoimmune hepatitis and drug induced liver disease as well as patients with recent infection and those who refused to be entitled in the study. 2. Patients will be excluded if they had a history of past excessive alcohol drinking for a period longer than 2 years at any time in the past 10 years. 3. Patients also will be excluded if they take medications known to cause steatosis or taking medications that have shown benefits in previous NASH pilot studies, including vitamin E, , thiazolidinedione, and alpha-glucosidase inhibitors. 4. Patients with a history of hypersensitivity to PTX or the methylxanthines (caffeine, theophylline, and theobromine) will be excluded, as well as those with a history of cerebral |
Country | Name | City | State |
---|---|---|---|
Egypt | Internal medicine and hepatology outpatient clinic at Ain Shams University Hospital. | Cairo |
Lead Sponsor | Collaborator |
---|---|
Al-Azhar University |
Egypt,
Girolami A. Tentative and updated classification of factor X variants. Acta Haematol. 1986;75(1):58-9. doi: 10.1159/000206084. No abstract available. — View Citation
Leoncini L, Vindigni C, Megha T, Funto I, Pacenti L, Musaro M, Renieri A, Seri M, Anagnostopoulos J, Tosi P. Epstein-Barr virus and gastric cancer: data and unanswered questions. Int J Cancer. 1993 Apr 1;53(6):898-901. doi: 10.1002/ijc.2910530605. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | improvement in liver aminotransferases(ALT and AST) | Difference between last and first measurements | 6 months compared to the baseline | |
Primary | NAFLD fibrosis score (NFS) | Change in NAFLD fibrosis score (NFS) (lower score means better outcome). | 6 months compared to the baseline | |
Secondary | The Aspartate (AST) to Platelet Ratio Index (APRI) score: | Change in (APRI) score (lower score means better outcome). | 6 months compared to the baseline | |
Secondary | The Fibrosis-4 (FIB-4) values: | Change in (FIB-4) values (lower values means better outcome). | 6 months compared to the baseline | |
Secondary | Serum Alkaline Phosphatase level (ALP) | Change in ALP serum level as inflammatory markers of NASH | 6 months compared to the baseline | |
Secondary | Serum Gamma-glutamyl Transferase level (GGT) | Change in GGT serum level as inflammatory markers of NASH | 6 months compared to the baseline | |
Secondary | Serum total and direct bilirubin. | Change in levels of serum total and direct bilirubin. | 6 months compared to the baseline | |
Secondary | Waist circumference | Change in waist circumference | 6 months compared to the baseline | |
Secondary | Change in anthropometric measures | including BMI etc. | 6 months compared to the baseline | |
Secondary | Lipid profile | Change in serum lipids | 6 months compared to the baseline | |
Secondary | Glycated hemoglobin (HbA1C) | Change in HbA1C level for patients with T2DM | 6 months compared to the baseline | |
Secondary | Fasting blood glucose level | Change in fasting blood glucose for patients with T2DM | 6 months compared to the baseline | |
Secondary | Drugs adverse events | Assessment of safety by reporting any adverse events | 6 months compared to the baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03289897 -
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
|
N/A | |
Active, not recruiting |
NCT05479721 -
LITMUS Imaging Study
|
||
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Recruiting |
NCT04976283 -
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
|
Phase 4 | |
Completed |
NCT02784444 -
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
|
Phase 2 | |
Not yet recruiting |
NCT05499949 -
The Franciscus Obesity NASH Study
|
||
Completed |
NCT04321343 -
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Recruiting |
NCT04371042 -
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
|
||
Not yet recruiting |
NCT03648554 -
Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)
|
Phase 4 | |
Completed |
NCT04972396 -
ALT-801 DDI Study in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03748628 -
Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects
|
Phase 1 | |
Enrolling by invitation |
NCT05195944 -
Semaglutide vs Sitagliptin
|
Phase 4 | |
Completed |
NCT04643795 -
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
|
Phase 1 | |
Terminated |
NCT03669133 -
Vitamin E for NASH Treatment in HIV Infected Individuals
|
Phase 2 | |
Completed |
NCT04066400 -
Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis
|
N/A | |
Completed |
NCT03536650 -
Effect of DMR in the Treatment of NASH
|
N/A | |
Completed |
NCT03783897 -
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
|
Phase 1 | |
Completed |
NCT04618744 -
A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Active, not recruiting |
NCT05338034 -
Phase 2a Study of HPG1860 in Subjects With NASH
|
Phase 2 | |
Active, not recruiting |
NCT04653103 -
NASH in Subjects With Different Classes of Obesity
|